SCHEMBL94598

SCHEMBL94598

[CH2]c1ccc(NC(=O)c2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.59
POLB P06746 3/20 0.59
NPC1 O15118 8/20 0.58
RAB9A P51151 8/20 0.58
MAPT P10636 6/20 0.58
RXFP1 Q9HBX9 2/20 0.58
LMNA P02545 2/20 0.58
APOBEC3G Q9HC16 1/20 0.58
KDM4E B2RXH2 1/20 0.58
MAPK1 P28482 1/20 0.58
CACNA1B Q00975 1/20 0.56
APBA1 Q02410 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.55
PKM P14618 2/20 0.55
TP53 P04637 2/20 0.55
ALOX15 P16050 2/20 0.55
ATM Q13315 1/20 0.55
MEN1 O00255 2/20 0.53
APEX1 P27695 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6459176 0.90 NPC1 (0.69) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL94356 0.89 CACNA1B (0.71) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL95456 0.85 NPC1 (0.58) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL95844 0.85 RAB9A (0.81) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL8771885 0.85 KMT2A (0.63) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL13986883 0.85 CACNA1B (0.76) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL8978050 0.83 KMT2A (0.61) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL13719113 0.83 RAB9A (0.85) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL8978184 0.83 KMT2A (0.61) KMT2APOLBNPC1RAB9AMAPT
SCHEMBL7592024 0.83 KMT2A (0.81) KMT2APOLBNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KMT2A 1059/4885POLB 1340/4885NPC1 2361/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KMT2A 2732/4885POLB 4329/4885NPC1 2922/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KMT2A 2732/4885POLB 4329/4885NPC1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.